Capital One National Association cut its stake in Celgene Corporation (NASDAQ:CELG) by 1.5% during the third quarter, Holdings Channel reports. The fund owned 46,491 shares of the biopharmaceutical company’s stock after selling 715 shares during the period. Capital One National Association’s holdings in Celgene Corporation were worth $4,859,000 as of its most recent filing with the SEC.

Other large investors have also recently modified their holdings of the company. Atwood & Palmer Inc. boosted its stake in shares of Celgene Corporation by 1.7% in the second quarter. Atwood & Palmer Inc. now owns 156,343 shares of the biopharmaceutical company’s stock valued at $15,420,000 after buying an additional 2,543 shares during the last quarter. LS Investment Advisors LLC boosted its stake in Celgene Corporation by 1.4% in the second quarter. LS Investment Advisors LLC now owns 10,690 shares of the biopharmaceutical company’s stock worth $1,054,000 after buying an additional 152 shares in the last quarter. Checchi Capital Advisers LLC boosted its stake in Celgene Corporation by 27.5% in the second quarter. Checchi Capital Advisers LLC now owns 6,994 shares of the biopharmaceutical company’s stock worth $690,000 after buying an additional 1,509 shares in the last quarter. Westwood Management Corp IL boosted its stake in Celgene Corporation by 1.0% in the second quarter. Westwood Management Corp IL now owns 134,830 shares of the biopharmaceutical company’s stock worth $13,298,000 after buying an additional 1,300 shares in the last quarter. Finally, Macguire Cheswick & Tuttle Investment Counsel LLC boosted its stake in Celgene Corporation by 10.7% in the second quarter. Macguire Cheswick & Tuttle Investment Counsel LLC now owns 81,459 shares of the biopharmaceutical company’s stock worth $8,034,000 after buying an additional 7,867 shares in the last quarter. 76.32% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Shares of Celgene Corporation (NASDAQ:CELG) opened at 117.48 on Friday. The stock has a market cap of $91.07 billion, a PE ratio of 44.62 and a beta of 1.74. Celgene Corporation has a 52-week low of $93.05 and a 52-week high of $127.00. The company’s 50 day moving average price is $117.82 and its 200 day moving average price is $109.36.

Celgene Corporation (NASDAQ:CELG) last announced its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.48 by $0.10. Celgene Corporation had a return on equity of 70.48% and a net margin of 19.71%. The firm had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $2.84 billion. During the same period in the previous year, the business earned $1.23 EPS. The firm’s revenue for the quarter was up 27.8% on a year-over-year basis. On average, analysts anticipate that Celgene Corporation will post $5.92 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This piece was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was copied illegally and reposted in violation of U.S. and international copyright legislation. The original version of this piece can be viewed at http://www.dailypolitical.com/2017/01/14/capital-one-national-association-sells-715-shares-of-celgene-corporation-celg.html.

A number of equities research analysts have recently commented on the company. Vetr cut Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $129.09 target price on the stock. in a research note on Wednesday, December 14th. Oppenheimer Holdings, Inc. assumed coverage on Celgene Corporation in a research note on Tuesday, November 29th. They issued an “outperform” rating and a $141.00 target price on the stock. Piper Jaffray Companies reissued a “buy” rating on shares of Celgene Corporation in a research note on Tuesday, October 18th. BMO Capital Markets reissued an “outperform” rating and issued a $142.00 target price on shares of Celgene Corporation in a research note on Tuesday, December 6th. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $145.00 target price on shares of Celgene Corporation in a research note on Tuesday, December 20th. They noted that the move was a valuation call. Four investment analysts have rated the stock with a hold rating, twenty-six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $137.30.

In other Celgene Corporation news, major shareholder Corp /De/ Celgene bought 800,150 shares of the company’s stock in a transaction that occurred on Monday, October 24th. The shares were purchased at an average cost of $14.00 per share, for a total transaction of $11,202,100.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Michael A. Friedman sold 18,600 shares of the business’s stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $116.10, for a total value of $2,159,460.00. Following the transaction, the director now owns 18,600 shares in the company, valued at $2,159,460. The disclosure for this sale can be found here. Corporate insiders own 0.97% of the company’s stock.

About Celgene Corporation

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.